A team of scientists led by researchers from Roswell Park Cancer Institute in Buffalo have demonstrated that photoacoustic imaging (PAI) may be an effective tool for more accurately viewing and monitoring prostate cancer. Photoacoustic imaging of enabled good discrimination between cells with and without the cancer marker, PSMA. Read the article here.
From ZEROHour Newsletter: January 2017 The newly released “2017 Cancer Facts and Figures” report shows the negative impact of the USPSTF recommendation against the PSA test. Read the Newsletter.
Rise in Prostate Cancer Deaths Stems from Testing Recommendations Read More »
A pilot study at the Sunnybrook Health Sciences Centre determined the feasibility of using multiparametric prostate magnetic resonance imaging as the primary screening test for prostate cancer. Initial results showed that prostate magnetic resonance imaging was better to predict prostate cancer than prostate specific antigen in an unselected sample of the general population. Read the article here.
Scientists at Swansea University say they have made a breakthrough which could revolutionise prostate cancer treatment. Researchers at the university’s School of Medicine have developed a way of shrinking cancer cells using a harmless strain of salmonella bacteria. Read the article here.
Salmonella could shrink prostate cancer cells Read More »
The headline reads: ‘His disease has disappeared’: Man ‘cured’ of advanced prostate cancer with shock doses of testosterone A possible new treatment option? Read the article.
New Treatment for Advanced PC? Read More »
The survival rate for early-stage prostate cancer is 99 percent after 10 years, regardless of whether men undergo surgery, radiation or are “actively monitored,” according to studies published Wednesday. Researchers hailed the results as good news, saying they had been expecting a survival rate of 90 percent. This article is hopeful, but leaves questions. It’s not clear how ‘early is defined or whether the arms were truly randomized. Read the article, carefully.
Almost all men with early prostate cancer survive 10 years, regardless of treatment Read More »
In a Swedish study, a bacterial species, Propionibacterium acnes, was found in 60 per cent of the prostate cancer biopsies, as opposed to 26 per cent of the controls. Read the article here.
Acne Bacteria Plays A Role In Prostate Cancer Read More »
A revolutionary new DNA treatment technique involves having a simple DNA test of your tumour first. This then tells doctors precisely which drugs or therapies are most suited to you – rather than relying on the standard treatment. The genetic profiling of your tumour can also tell doctors which drugs you should avoid because they either won’t help you or are likely to give you worse side effects than others might suffer. Read the article.
Revolutionary new cancer treatment makes patients SIX TIMES more likely to survive Read More »
A clinical trial at Sunnybrook Hospital in Toronto will determine the effectiveness of a targeted radiotherapy approach, stereotactic body radiotherapy (SBRT), in improving outcomes for men with oligometastatic prostate cancer. Read the article.
Advances in targeted radiation for prostate cancer Read More »
A compound initially developed as a cholesterol-fighting agent not only halts the progression of prostate cancer, but also can kill cancerous cells, researchers at the University of Missouri have determined. Read the article.
Cholesterol-Lowering Agent Halts Prostate Cancer Read More »